Global Cancer Immunotherapy Market 2022-2026

The publisher has been monitoring the cancer immunotherapy market and it is poised to grow by $74.45 bn during 2022-2026, progressing at a CAGR of 14.67% during the forecast period. The report on the cancer immunotherapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of cancer and the rise in technological advancements in cancer immunotherapy.

The cancer immunotherapy market analysis includes the type segment and geographic landscape.

The cancer immunotherapy market is segmented as below:

By Type

Monoclonal antibodies
Cancer vaccines
Check point inhibitors and immunomodulators

By Geographical Landscape

North America
Europe
Asia
ROW

This study identifies the growing awareness among consumers regarding cancer immunotherapy as one of the prime reasons driving the cancer immunotherapy market growth during the next few years.

The report on cancer immunotherapy market covers the following areas:

Cancer immunotherapy market sizing
Cancer immunotherapy market forecast
Cancer immunotherapy market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer immunotherapy market vendors that include Amgen Inc., Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck KGaA, Novartis AG, and Pfizer Inc. Also, the cancer immunotherapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Executive Summary

Market Overview

Market Landscape

Market ecosystem
Value chain analysis

Market Sizing

Market definition
Market segment analysis
Market size 2021
Market outlook: Forecast for 2021 - 2026

Five Forces Analysis

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Type

Market segments
Comparison by Type
Monoclonal antibodies - Market size and forecast 2021-2026
Cancer vaccines - Market size and forecast 2021-2026
Check point inhibitors and immunomodulators - Market size and forecast 2021-2026
Market opportunity by Type

Customer landscape

Geographic Landscape

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2021-2026
Europe - Market size and forecast 2021-2026
Asia - Market size and forecast 2021-2026
ROW - Market size and forecast 2021-2026
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape

Landscape disruption

Vendor Analysis

Vendors covered
Market positioning of vendors
Amgen Inc.
Bayer AG
Bristol-Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson and Johnson Inc.
Merck KGaA
Novartis AG
Pfizer Inc.

Appendix

Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

List of Exhibits

Key Finding 1
Key Finding 2
Key Finding 3
Key Finding 5
Key Finding 6
Key Finding 7
Key Finding 8
Parent market
Market characteristics
Offerings of vendors included in the market definition
Market segments
Global - Market size and forecast 2021 - 2026 ($ million)
Global market: Year-over-year growth 2021 - 2026 (%)
Five forces analysis 2021 & 2026
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition - Five forces 2021
Type - Market share 2021-2026 (%)
Comparison by Type
Monoclonal antibodies - Market size and forecast 2021-2026 ($ million)
Monoclonal antibodies - Year-over-year growth 2021-2026 (%)
Cancer vaccines - Market size and forecast 2021-2026 ($ million)
Cancer vaccines - Year-over-year growth 2021-2026 (%)
Check point inhibitors and immunomodulators - Market size and forecast 2021-2026 ($ million)
Check point inhibitors and immunomodulators - Year-over-year growth 2021-2026 (%)
Market opportunity by Type
Customer landscape
Market share By Geographical Landscape 2021-2026 (%)
Geographic comparison
North America - Market size and forecast 2021-2026 ($ million)
North America - Year-over-year growth 2021-2026 (%)
Europe - Market size and forecast 2021-2026 ($ million)
Europe - Year-over-year growth 2021-2026 (%)
Asia - Market size and forecast 2021-2026 ($ million)
Asia - Year-over-year growth 2021-2026 (%)
ROW - Market size and forecast 2021-2026 ($ million)
ROW - Year-over-year growth 2021-2026 (%)
Key leading countries
Market opportunity By Geographical Landscape ($ million)
Impact of drivers and challenges
Vendor landscape
Landscape disruption
Industry risks
Vendors covered
Market positioning of vendors
Amgen Inc. - Overview
Amgen Inc. - Business segments
Amgen Inc. - Key offerings
Amgen Inc. - Key customers
Amgen Inc. - Segment focus
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key offerings
Bayer AG - Key customers
Bayer AG - Segment focus
Bristol-Myers Squibb Co. - Overview
Bristol-Myers Squibb Co. - Product and service
Bristol-Myers Squibb Co. - Key offerings
Bristol-Myers Squibb Co. - Key customers
Bristol-Myers Squibb Co. - Segment focus
Eli Lilly and Co. - Overview
Eli Lilly and Co. - Business segments
Eli Lilly and Co. - Key offerings
Eli Lilly and Co. - Key customers
Eli Lilly and Co. - Segment focus
F. Hoffmann-La Roche Ltd. - Overview
F. Hoffmann-La Roche Ltd. - Business segments
F. Hoffmann-La Roche Ltd. - Key offerings
F. Hoffmann-La Roche Ltd. - Key customers
F. Hoffmann-La Roche Ltd. - Segment focus
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Key customers
GlaxoSmithKline Plc - Segment focus
Johnson and Johnson Inc. - Overview
Johnson and Johnson Inc. - Business segments
Johnson and Johnson Inc. - Key offerings
Johnson and Johnson Inc. - Key customers
Johnson and Johnson Inc. - Segment focus
Merck KGaA - Overview
Merck KGaA - Business segments
Merck KGaA - Key offerings
Merck KGaA - Key customers
Merck KGaA - Segment focus
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key offerings
Novartis AG - Key customers
Novartis AG - Segment focus
Pfizer Inc. - Overview
Pfizer Inc. - Business segments
Pfizer Inc. - Key offerings
Pfizer Inc. - Key customers
Pfizer Inc. - Segment focus
Currency conversion rates for US$
Research Methodology
Validation techniques employed for market sizing
Information sources
List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global cancer immunotherapy market: Amgen Inc., Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck KGaA, Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is growing awareness among consumers regarding cancer immunotherapy.`

According to the report, one of the major drivers for this market is the high prevalence of cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.